Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease

Abstract:  Melatonin is an endogenous antioxidant and free radical scavenger. A transgenic (Tg) mouse model for Alzheimer's disease mimics the accumulation of senile plaques, neuronal apoptosis and memory impairment. Previous studies indicated that melatonin reduced β‐amyloid (Aβ)‐induced neurotoxicity. In this study, after giving melatonin at 10 mg/kg to APP 695 transgenic (APP 695 Tg) mice for 4 months, we evaluated the long‐term influence of melatonin on behavior, biochemical and neuropathologic changes in APP 695 Tg mice. Step‐down and step‐through passive avoidance tests suggested that 8‐month‐old APP 695 Tg mice showed decreases in step‐down latency and step‐through latency and increases in count of error throughout the entire learning trial and memory session, which suggested learning and memory impairment. However, melatonin alleviated learning and memory deficits. Additionally, choline acetyltransferase (ChAT) activity also decreased in the frontal cortex and hippocampus of APP 695 Tg mice compared with non‐Tg littermates. Melatonin supplementation increased ChAT activity in the frontal cortex and hippocampus. DNA fragmentation was present in the frontal cortex of the APP 695 Tg mice; melatonin reduced the number of apoptotic neurons. Congo Red staining and Bielschowsky silver impregnation both showed the apparent extracellular Aβ deposition in frontal cortex of APP 695 Tg mice. However, melatonin decreased the Aβ deposits. Our results indicate that neuroprotection by melatonin is partly related to modulation of apoptosis and protection of the cholinergic system. Early rational melatonin interventions may be one of the most promising strategies in the development of approaches to retard or prevent Aβ‐mediated disease progression.

[1]  R. Reiter,et al.  Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. , 2002, Current topics in medicinal chemistry.

[2]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[3]  George Perry,et al.  The neuroprotective activities of melatonin against the Alzheimer β‐protein are not mediated by melatonin membrane receptors , 2002, Journal of pineal research.

[4]  A. Hirano,et al.  A COMPARATIVE STUDY OF MODIFIED BIELSCHOWSKY, BODIAN AND THIOFLAVIN S STAINS ON ALZHEIMER'S NEUROFIBRILLARY TANGLES , 1986, Neuropathology and applied neurobiology.

[5]  F. van Leuven.  Single and multiple transgenic mice as models for Alzheimer's disease. , 2000, Progress in neurobiology.

[6]  R. D'Hooge,et al.  Age‐dependent cognitive decline in the APP23 model precedes amyloid deposition , 2003, The European journal of neuroscience.

[7]  R. Reiter,et al.  The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. , 1993, Cancer letters.

[8]  C. Soto,et al.  Inhibition of Alzheimer b-Fibrillogenesis by Melatonin* , 1998 .

[9]  R. Reiter.  Oxidative damage in the central nervous system: protection by melatonin , 1998, Progress in Neurobiology.

[10]  M. Vila,et al.  Neurological diseases: Targeting programmed cell death in neurodegenerative diseases , 2003, Nature Reviews Neuroscience.

[11]  F. Wolfgram,et al.  Spectrophotometric assay for choline acetyltransferase. , 1972, Analytical biochemistry.

[12]  G. Higgins,et al.  Transgenic mouse models of Alzheimer's disease: phenotype and application , 2003, Behavioural pharmacology.

[13]  C. Hess,et al.  Melatonin protects SHSY5Y neuroblastoma cells from cobalt‐induced oxidative stress, neurotoxicity and increased β‐amyloid secretion , 2001, Journal of pineal research.

[14]  I. Izquierdo,et al.  Mechanisms for memory types differ , 1998, Nature.

[15]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[16]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[17]  D. Westaway,et al.  Mouse models of Alzheimer's disease: The long and filamentous road , 2003, Neurological research.

[18]  L. Chao.  Spectrophotometric determination of choline acetyltransferase in the presence of dithiothreitol. , 1978, Analytical biochemistry.

[19]  D. Moechars,et al.  Acetylcholinesterase-Positive Fiber Deafferentation and Cell Shrinkage in the Septohippocampal Pathway of Aged Amyloid Precursor Protein London Mutant Transgenic Mice , 2000, Neurobiology of Disease.

[20]  D. Acuña-Castroviejo,et al.  Free Radical‐Mediated Molecular Damage , 2001, Annals of the New York Academy of Sciences.

[21]  Brian J Cummings,et al.  Immunohistochemical evidence for apoptosis in Alzheimer's disease. , 1994, Neuroreport.

[22]  Koji Abe,et al.  Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease , 2003, Journal of neurochemistry.

[23]  K. Jellinger,et al.  Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. , 1999, The American journal of pathology.

[24]  B. Poeggeler,et al.  Potent Neuroprotective Properties against the Alzheimer β-Amyloid by an Endogenous Melatonin-related Indole Structure, Indole-3-propionic Acid* , 1999, The Journal of Biological Chemistry.

[25]  Q. Chuan,et al.  Establishment of the transgenic model of Alzheimers disease , 2000, Neurobiology of Aging.

[26]  C. Cotman,et al.  Caspase-9 Activation and Caspase Cleavage of tau in the Alzheimer's Disease Brain , 2002, Neurobiology of Disease.

[27]  P. Kelly,et al.  Progressive age-related impairment of cognitive behavior in APP23 transgenic mice , 2003, Neurobiology of Aging.

[28]  D. Wolfer,et al.  Enriched early experiences of mice underexpressing the β‐amyloid precursor protein restore spatial learning capabilities but not normal openfield behavior of adult animals , 2002, Genes, brain, and behavior.

[29]  P. Chyka,et al.  Problems in assessment of acute melatonin overdose. , 1997, Southern medical journal.

[30]  J. Rossier,et al.  Benzodiazepine impairs and β-carboline enhances performance in learning and memory tasks , 1986, Nature.

[31]  E. Muñoz-Delgado,et al.  Amphiphilic and hydrophilic forms of acetyl‐ and butyrylcholinesterase in human brain , 1993, Journal of neuroscience research.

[32]  William H. Nesse,et al.  Activation of Caspase-8 in the Alzheimer's Disease Brain , 2001, Neurobiology of Disease.

[33]  C. Finch,et al.  Relation of neuronal APP-751/APP-695 mRNA ratio and neuritic plaque density in Alzheimer's disease. , 1990, Science.

[34]  J. Wehner,et al.  Assessment of learning by the Morris water task and fear conditioning in inbred mouse strains and F1 hybrids: implications of genetic background for single gene mutations and quantitative trait loci analyses , 1997, Neuroscience.

[35]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[37]  D F Swaab,et al.  Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. , 1999, The Journal of clinical endocrinology and metabolism.

[38]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[39]  M. Staufenbiel,et al.  Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation , 2002, Brain Research.

[40]  W. Kamphorst,et al.  Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels , 2003, Journal of pineal research.

[41]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[42]  B. Sommer,et al.  Neuron loss in APP transgenic mice , 1998, Nature.

[43]  J. Morrison,et al.  Life and death of neurons in the aging brain. , 1997, Science.